Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Raptor Pharma (RPTP) Gains on New PROCYSBI Patents and Orphan Drug Exclusivity Extension
January 25, 2016 10:22 AM ESTRaptor Pharma (NASDAQ: RPTP) is gaining sharply after the company announced this morning that a U.S. PROCYSBI patent, number 9,233,077, is now... More
Raptor Pharma (RPTP) Announces FDA Orange Book Listing of PROCYSBI Patent
January 25, 2016 7:09 AM ESTRaptor Pharmaceutical Corp. (Nasdaq: RPTP) announced that a U.S. PROCYSBI patent, number 9,233,077, is now listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent, entitled Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same, covers the enteric coated micro-bead formulation of PROCYSBI as well as other related formulations. This... More
